Table 2.
Summary of meta-analyses.
| Endpoint | HR/OR (95% CI) | P-value | No. of studies |
|---|---|---|---|
| EFS | 1.01 (0.92, 1.11) | 0.78 | 20 |
| 1-year EFS | 0.83 (0.67, 1.02) | 0.07 | 19 |
| 3-year EFS | 1.05 (0.92, 1.20) | 0.47 | 19 |
| 5-year EFS | 1.06 (0.91, 1.23) | 0.46 | 19 |
| OS | 1.02 (0.92, 1.14) | 0.66 | 13 |
| 1-year OS | 0.99 (0.75, 1.30) | 0.92 | 13 |
| 3-year OS | 1.00 (0.84, 1.19) | 1.00 | 13 |
| 5-year OS | 1.02 (0.89, 1.17) | 0.75 | 13 |
| RR | 1.16 (0.81, 1.66) | 0.40 | 11 |
| AEs, overall | 1.02 (0.59, 1.74) | 0.95 | 10 |
| Nausea/vomiting | 0.56 (0.27, 1.16) | 0.12 | 4 |
| Leukopenia | 0.82 (0.40, 1.68) | 0.58 | 9 |
Abbreviations: AE, adverse event; CI, confidence interval; EFS, event-free survival; HR, hazard ratio; OR, odds ratio; OS, overall survival; RR, response rate.